期刊文献+

全自动免疫组化法与手工免疫组化法检测卵巢癌ALK蛋白表达的对比分析 被引量:2

Comparative Study of ALK Antibody in Ovarian Cancer between Manual and Automatic Immunohistochemical Detection
下载PDF
导出
摘要 目的探讨全自动免疫组化法与手工免疫组化法检测ALK(anaplastic lymphoma kinase,ALK)在卵巢癌中的表达,并对两者进行比较。方法选取53例卵巢癌组织的石蜡病理,应用抗体ALK(D5F3)全自动IHC法联合抗ALK(5A4)手工IHC法分别检测卵巢癌中ALK蛋白水平,并对两种方法进行比较。结果抗ALK(D5F3)检测发现ALK在卵巢癌组织中表达,阳性率9.43%(5/53),而抗ALK(5A4)组化法未检测出卵巢癌组织中有ALK蛋白表达。结论ALK蛋白在卵巢癌中有表达,抗D5F3全自动IHC法优于抗5A4手工免疫组化法,抗D5F3联合全自动免疫组化法敏感度更高。 Objective To investigate the detection and comparison of ALK(ALK)in ovarian cancer by automatic immunohistochemistry and manual immunohisto-chemistry.Methods The paraffin pathology of 53 ovarian cancer tissues was selected,and ALK protein levels in ovarian cancer were detected by ALK(D5F3)automatic IHC method combined with ALK(5A4)manual IHC method,and the two methods were compared.Results Anti-alk(D5F3)test showed that ALK was expressed in ovarian cancer tissues with a positive rate of 9.43%(5/53),while anti-alk(5A4)histochemistry method did not detect the expression of ALK protein in ovarian cancer tissues.Conclusion ALK protein is expressed in ovarian cancer.The automatic IHC method against D5F3 is superior to the manual immunohistochemical method against 5A4.
作者 罗文姬 李瑞珍 罗清平 余光银 魏蔚霞 LUO Wen-ji;YU Guang-yin;LI Rui-zhen(Department of Gynaecology and Obstetrics,Peking University Shenzhen Hospital,Shenzhen 518036,Guangdong Province,China)
出处 《罕少疾病杂志》 2019年第5期35-37,共3页 Journal of Rare and Uncommon Diseases
关键词 卵巢癌 间变性淋巴瘤激酶(ALK) 全自动免疫组化学(IHC) Ovarian Cancer ALK Automated Immunohistochemistry
  • 相关文献

参考文献7

二级参考文献82

  • 1Soda M,Choi YL,Enomoto M,et al.Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer.Nature,2007,448(7153):561-566.
  • 2Wong DW,Leung EL,So KK,et al.The EML4 ALK fusion gene is involved in various histologic types of lung cancers from nonsmokers with wild-type EGFR and KRAS.Cancer,2009,115(8):1723-1733.
  • 3Shaw AT,Yeap BY,Mino-Kenudson M,et al.Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK.J Clin Oncol,2009,27(26):4247-4253.
  • 4Shaw AT.Phase 3 randomized study of crizotinib versus pemetrexed or docetaxel chemotherapy in advanced,ALK-positive NSCLC (PROFILE 1007).35th ESMO,2012,abstract LBA1.
  • 5全国肿瘤防治研究办公室/全国肿瘤登记中心/卫生部疾病预防控制局.2009全国肿瘤登记年报.北京:军事医学科学出版社.2010.
  • 6Rikova K,Guo A,Zeng Q,et al.Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer.Cell,2007,131 (6):1190-1203.
  • 7Mitsudomi T,Suda K,Tomizawa K,et al.Clinico-pathologic features of lung cancer with EML4-ALK translocation.J Clin Oncol,2010 (suppl):abstr 10598.
  • 8Zhang X,Zhang S,Yang X,et al.Fusion of EML4 and ALK is associated with development of lung adenocarcinomas lacking EGFR and KRAS mutations and is correlated with ALK expression.Mol Cancer,2010,9:188.
  • 9Wu SG,Kuo YW,Chang YL,et al.EML4-ALK translocation predicts better outcome in lung adenocarcinoma patients with wildtype EGFR.J Thorac Oucol,2012,7(1):98-104.
  • 10Rodig SJ,Mino-Kenudson M,Dacic S,et al.Unique clinicopathologic features characterize ALK-rearranged lung adenocarcinoma in the western population.Clin Cancer Res,2009,15(16):5216-5223.

共引文献112

同被引文献32

引证文献2

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部